Shares of BTG plc (LON:BTG) have received an average recommendation of “Buy” from the ten analysts that are presently covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month price objective among brokers that have covered the stock in the last year is GBX 766.44 ($9.93).

Several equities research analysts recently weighed in on BTG shares. Investec reaffirmed a “buy” rating and set a GBX 720 ($9.33) price objective on shares of BTG plc in a research report on Thursday, April 6th. Numis Securities Ltd reissued a “buy” rating and issued a GBX 900 ($11.66) target price on shares of BTG plc in a report on Tuesday, April 4th. Stifel Nicolaus reissued a “buy” rating and issued a GBX 725 ($9.39) target price on shares of BTG plc in a report on Tuesday, April 4th. Panmure Gordon increased their target price on shares of BTG plc from GBX 737 ($9.55) to GBX 809 ($10.48) and gave the stock a “buy” rating in a report on Tuesday, May 16th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a GBX 775 ($10.04) target price on shares of BTG plc in a report on Tuesday, May 16th.

Shares of BTG plc (BTG) opened at 669.00 on Friday. BTG plc has a 12 month low of GBX 528.36 and a 12 month high of GBX 739.50. The company’s 50 day moving average is GBX 673.94 and its 200-day moving average is GBX 613.59. The firm’s market cap is GBX 2.58 billion.

In other news, insider Rolf Soderstrom sold 22,624 shares of the company’s stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of GBX 649 ($8.41), for a total value of £146,829.76 ($190,193.99).

COPYRIGHT VIOLATION NOTICE: This article was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/07/14/btg-plc-btg-receives-consensus-recommendation-of-buy-from-brokerages.html.

BTG plc Company Profile

BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.

Analyst Recommendations for BTG plc (LON:BTG)

Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with MarketBeat.com's FREE daily email newsletter.